Bayer-Supported 'Power+' Project Launches to Enhance Postprandial Glucose Management via Internet-Based Diabetes Education

It is reported that the “Power+ China Postprandial Blood Glucose Optimization Management Platform Project” will be implemented across 220 general hospitals nationwide to optimize postprandial blood glucose management both in-hospital and out-of-hospital. Spearheaded by 1,000 diabetes specialists, the project will provide a three-month service of optimized postprandial blood glucose management through online health consultations via the Datangyi APP (the China Postprandial Blood Glucose Optimization Management Platform) and offline patient education activities, guiding patients in scientific self-management of blood glucose. Approximately 80,000 newly diagnosed patients with elevated postprandial blood glucose and patients with suboptimal postprandial blood glucose control are expected to benefit from this initiative.

Bayer has been committed to advancing diabetes patient management and education in China. Since 2006, the company has made numerous efforts in the field of diabetes management and education. With the “Power+ China Postprandial Blood Glucose Optimization Management Platform” project, Bayer has chosen to leverage a mobile health platform to deliver diabetes patient education and management in diverse ways, reaching a broader audience with more personalized approaches, particularly focusing on optimizing postprandial blood glucose control to achieve target goals.

It is understood that Da Tang Yi, the mobile healthcare service provider for this project, primarily offers physicians services in five areas: scientific research and education, brand building, patient management, compliant income generation, and social networking. From the outset of product design, Da Tang Yi positioned itself to facilitate doctor-patient communication and follow-up care outside hospital settings. By leveraging professional medical expertise combined with the advantages of the internet, it aims to achieve more intelligent disease control and efficient out-of-hospital follow-up. Gu Bin, Founder and Chairman of Da Tang Yi, stated that to date, the platform has registered 15,000 physicians and served nearly 300,000 patients.

Facilitating the Individualized Setting of Glycemic Management Goals and the Individualized Selection of Treatment

According to the Diabetes Atlas published by the International Diabetes Federation (IDF) in 2015, the number of patients with diabetes in China has reached 100 million, meaning that one-quarter of the global diabetic population resides in China. Due to factors such as genetic profiles and β-cell functional characteristics specific to the Chinese population, patients in China more commonly present with elevated postprandial blood glucose levels. Epidemiological data indicate that 82% of patients with diabetes exhibit elevated postprandial blood glucose. Notably, among newly diagnosed cases, up to 47% present with “isolated” postprandial hyperglycemia. Furthermore, there is a trend toward younger age at onset, with more than half of these patients being under 50 years of age.

Elevated postprandial blood glucose significantly increases the risk of macrovascular complications in diabetes, such as myocardial infarction and cardiac death, and is closely associated with microvascular complications including retinopathy and chronic kidney disease. However, unlike fasting blood glucose, postprandial blood glucose measurement requires testing two hours after a meal. Due to significant limitations in conducting this test within hospital settings, most patients primarily perform self-monitoring at home. Furthermore, postprandial blood glucose levels are influenced not only by medication but also by dietary and exercise management. Therefore, for patients with type 2 diabetes, particularly newly diagnosed individuals lacking experience in self-monitoring of blood glucose, achieving target postprandial glucose levels presents greater challenges, underscoring the need for strengthened out-of-hospital management.

In response to these challenges, in 2015, Professor Mu Yiming, Chairman of the Chinese Society of Endocrinology of the Chinese Medical Association, led a team comprising Ji Linong, Zhu Dalong, and more than 20 other experts in the field of diabetes in China to jointly develop the “Expert Consensus on the Management of Postprandial Hyperglycemia in Chinese Patients with Type 2 Diabetes.” This consensus emphasized the urgency of managing postprandial blood glucose and further specified target values for postprandial blood glucose based on individual patient characteristics—such as age, duration of diabetes, and length of treatment—as well as the need to prevent hypoglycemia. Specifically, the general target for postprandial blood glucose is no higher than 10.0 mmol/L. However, for patients who are newly diagnosed, have a shorter disease duration, and are younger, stricter postprandial blood glucose targets (below 7.8 mmol/L) should be achieved to ensure better long-term outcomes, given their longer life expectancy.

This also means that endocrinologists often need to manage multiple patients with diabetes, each presenting with distinct disease characteristics, treatment landscapes, and expectations. Therefore, it is crucial to enhance the individualized setting of glycemic control targets and the personalized selection of therapies. This approach can effectively ensure that patients in China achieve stable glycemic targets and reduce the incidence of complications. In light of this, to further address the challenges of out-of-hospital management of postprandial glucose and to implement the expert consensus on postprandial glucose, the Chinese Red Cross Foundation has launched the China Postprandial Glucose Optimization Management Platform Project.

According to Professor Guo Xiaohui, Head of the Education and Management Group of the Diabetes Branch of the Chinese Medical Association: “By using the Power+ China Postprandial Glucose Optimization Platform APP, patients can not only easily record blood glucose data and interact with their dedicated physicians for online health consultations, but also receive personalized diabetes education. Meanwhile, physicians can organize online and offline patient education programs through the China Postprandial Glucose Optimization Management Platform and push educational articles tailored to individual patient needs. Leveraging the efficiency and convenience of new media, this approach enables patients to enjoy personalized blood glucose management while allowing physicians to closely monitor patients’ blood glucose levels and formulate individualized management plans. This fosters close engagement from both parties, ensuring that patients benefit from mobile healthcare in managing their postprandial blood glucose.”

Previously, VCBeat published an article titled “Partnering with Da Te Bao: How Da Tang Yi’s “Blood Sugar Control Insurance Service Package” Works,” reporting on Datangyi’s products and its insurance-related plans. Following the event, our reporter conducted an exclusive interview with Datangyi’s CEO to gain insights into his latest perspectives on “Internet + Chronic Disease Management.” Stay tuned to VCBeat for more updates.